Hannah McCulloch
Hannah McCulloch has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Paula Baraitser
SH:24 CIC, London, UK
4 shared publications Kalina Mihaylova
Anne’s Day Ltd (Daye)
3 shared publications- Michelle Gomes
Daye
3 shared publications - Patricia A. Lohr
Centre for Reproductive Research & Communication, British Pregnancy Advisory Service (BPAS), London, UK
3 shared publications Valentina Milanova
Anne’s Day Ltd (Daye)
3 shared publications- Chris Howroyd
SH:24, London, United Kingdom
2 shared publications
Latest Publications
- 18 March 2026
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 148 (1) , 80-86
Accuracy of Menstrual History for Determining Gestational Age Among Adolescents Who Underwent Abortion in England and Wales
OBJECTIVE: To assess the accuracy of using the last menstrual period (LMP) date for determining gestational age, compared with ultrasonography, among patients aged younger than 16 years at British Pregnancy Advisory Service (BPAS), a large national abortion service in England and Wales. This evaluation was undertaken in the context of national discussion and guidance about adolescent no-test medication abortion access. METHODS: We analyzed routinely collected gestational age data for all patients younger than 16 (herein referred to as adolescents) who underwent abortion at BPAS between May 1, 2021, and April 30, 2024. We compared gestational age from ultrasonography (reference) to that from LMP date, overall and by eligibility for no-test medication abortion (where ineligibility was indicated by an unknown gestational age or gestation that exceeded 69 days). We calculated diagnostic measures of accuracy that included sensitivity, specificity, and proportion of false-negative results. For a subsample, we incorporated additional menstrual history indicators into a composite screening variable and recalculated measures. RESULTS: During the evaluation period, 1,555 adolescents underwent abortion; 1,282 (82.4%) provided an LMP date. On average, LMP dating overestimated gestational age by 3 days compared with ultrasonography. When using the LMP date alone, the sensitivity for correctly detecting ineligible patients was 86.6% (95% CI, 82.5–90.1) and the specificity for correctly identifying eligible patients was 78.8% (95% CI, 76.4–81.1). The proportion of false-negative results (patients incorrectly classified as eligible) was 2.8% (95% CI, 2.0–3.7). With the composite measure, sensitivity rose to 93.9% (95% CI, 90.8–96.2, P <.05) but specificity declined to 54.2% (95% CI, 51.4–57.0). The false-negative proportion reduced to 1.3% (95% CI, 0.7–1.9), including 0.5% with a gestational age beyond 83 days (8/1,555) on ultrasonography. CONCLUSION: Menstrual dating provides high sensitivity for identifying adolescents as ineligible for no-test medication abortion, with very low risk of clinically important misclassification. Adding menstrual history indicators improves sensitivity but indicates unnecessary scans for many eligible individuals. Policy must balance the rare risk of misestimation against costs of restricting adolescents' access, where disproportionate care barriers already exist.
- 18 March 2026
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 148 (1) , 80-86
Accuracy of Menstrual History for Determining Gestational Age Among Adolescents Who Underwent Abortion in England and Wales
OBJECTIVE: To assess the accuracy of using the last menstrual period (LMP) date for determining gestational age, compared with ultrasonography, among patients aged younger than 16 years at British Pregnancy Advisory Service (BPAS), a large national abortion service in England and Wales. This evaluation was undertaken in the context of national discussion and guidance about adolescent no-test medication abortion access. METHODS: We analyzed routinely collected gestational age data for all patients younger than 16 (herein referred to as adolescents) who underwent abortion at BPAS between May 1, 2021, and April 30, 2024. We compared gestational age from ultrasonography (reference) to that from LMP date, overall and by eligibility for no-test medication abortion (where ineligibility was indicated by an unknown gestational age or gestation that exceeded 69 days). We calculated diagnostic measures of accuracy that included sensitivity, specificity, and proportion of false-negative results. For a subsample, we incorporated additional menstrual history indicators into a composite screening variable and recalculated measures. RESULTS: During the evaluation period, 1,555 adolescents underwent abortion; 1,282 (82.4%) provided an LMP date. On average, LMP dating overestimated gestational age by 3 days compared with ultrasonography. When using the LMP date alone, the sensitivity for correctly detecting ineligible patients was 86.6% (95% CI, 82.5–90.1) and the specificity for correctly identifying eligible patients was 78.8% (95% CI, 76.4–81.1). The proportion of false-negative results (patients incorrectly classified as eligible) was 2.8% (95% CI, 2.0–3.7). With the composite measure, sensitivity rose to 93.9% (95% CI, 90.8–96.2, P <.05) but specificity declined to 54.2% (95% CI, 51.4–57.0). The false-negative proportion reduced to 1.3% (95% CI, 0.7–1.9), including 0.5% with a gestational age beyond 83 days (8/1,555) on ultrasonography. CONCLUSION: Menstrual dating provides high sensitivity for identifying adolescents as ineligible for no-test medication abortion, with very low risk of clinically important misclassification. Adding menstrual history indicators improves sensitivity but indicates unnecessary scans for many eligible individuals. Policy must balance the rare risk of misestimation against costs of restricting adolescents' access, where disproportionate care barriers already exist.
- Open Access
Acceptability of diagnostic tampon self-sampling for HPV: Mixed methods findings from the STAMP Trial and focus groups
Background Multiple barriers limit access to traditional in-person clinician sampling for cervical cancer. The STAMP (Screening with Tampons: Evaluating Diagnostic Accuracy for HPV and Assessing Participant Views) study evaluated the diagnostic accuracy and acceptability of tampon-based self-sampling for HPV amongst people assigned female at birth. Encouraging technical performance of the tampon as a sample for microbial detection was observed relative to clinician-taken samples. Pre and post trial questionnaires and a nested qualitative study explored acceptability. Methods All participants (n=263) completed questionnaires before and after sampling using three methods: tampon-based self-sampling, swab-based self-sampling, and clinician-collected samples. Questions included comfort, trust and ease of use of tampon-sampling. Four focus groups (n=24) were conducted online, and analysed using reflexive thematic analysis. Results Questionnaire responses suggested tampon-based self-sampling was highly acceptable. Qualitative analysis identified four key themes: advantages of self-sampling over clinician-sampling; unique benefits of tampon-based self-sampling; concerns about accuracy and trust; and confidence in correct use. Participants valued the physical comfort, psychological ease, and practical convenience of self-sampling compared to clinician-sampling. The familiarity of tampons as an everyday product was central to acceptability, normalising screening. While some initially questioned accuracy, most were reassured by evidence of performance. Clear instructions and understanding the evidence base boosted confidence. Conclusion Findings suggest that tampon-based self-sampling is a highly acceptable alternative sampling approach for cervical screening that may increase screening participation by addressing multiple barriers. Implementation strategies should emphasise the method’s everyday nature, while providing accessible guidance to support correct usage. What is already known on this topic Self-sampling for Human Papillomavirus (HPV) has been recommended by the World Health Organisation as an additional approach to expand cervical cancer screening services, complementing conventional clinician-taken sampling to broaden access and address barriers associated with in-person care. What this study adds Findings from this study suggest that self-sampling has the potential to support screening for cervical cancer as an acceptable, at-home approach addressing physical, psychological and practical barriers associated with traditional clinician collected sampling. Participants reported that the familiarity of using a tampon for self-sampling creates a unique advantage over other self-sampling methods through demedicalising and normalising screening, therefore potentially increasing accessibility and participation among underscreened populations who experience most barriers. How this study might affect research, practice or policy Self-sampling including tampon-based self sampling offers a promising, acceptable approach to achieving cancer elimination goals. Implementation of tampon-based self-sampling for HPV should be clear, comprehensive and accessible, incorporating visual aids and simple language while emphasising the rationale and scientific evidence behind the collection method
Open AccessAcceptability of diagnostic tampon self-sampling for HPV: Mixed methods findings from the STAMP Trial and focus groups
Background Multiple barriers limit access to traditional in-person clinician sampling for cervical cancer. The STAMP (Screening with Tampons: Evaluating Diagnostic Accuracy for HPV and Assessing Participant Views) study evaluated the diagnostic accuracy and acceptability of tampon-based self-sampling for HPV amongst people assigned female at birth. Encouraging technical performance of the tampon as a sample for microbial detection was observed relative to clinician-taken samples. Pre and post trial questionnaires and a nested qualitative study explored acceptability. Methods All participants (n=263) completed questionnaires before and after sampling using three methods: tampon-based self-sampling, swab-based self-sampling, and clinician-collected samples. Questions included comfort, trust and ease of use of tampon-sampling. Four focus groups (n=24) were conducted online, and analysed using reflexive thematic analysis. Results Questionnaire responses suggested tampon-based self-sampling was highly acceptable. Qualitative analysis identified four key themes: advantages of self-sampling over clinician-sampling; unique benefits of tampon-based self-sampling; concerns about accuracy and trust; and confidence in correct use. Participants valued the physical comfort, psychological ease, and practical convenience of self-sampling compared to clinician-sampling. The familiarity of tampons as an everyday product was central to acceptability, normalising screening. While some initially questioned accuracy, most were reassured by evidence of performance. Clear instructions and understanding the evidence base boosted confidence. Conclusion Findings suggest that tampon-based self-sampling is a highly acceptable alternative sampling approach for cervical screening that may increase screening participation by addressing multiple barriers. Implementation strategies should emphasise the method’s everyday nature, while providing accessible guidance to support correct usage. What is already known on this topic Self-sampling for Human Papillomavirus (HPV) has been recommended by the World Health Organisation as an additional approach to expand cervical cancer screening services, complementing conventional clinician-taken sampling to broaden access and address barriers associated with in-person care. What this study adds Findings from this study suggest that self-sampling has the potential to support screening for cervical cancer as an acceptable, at-home approach addressing physical, psychological and practical barriers associated with traditional clinician collected sampling. Participants reported that the familiarity of using a tampon for self-sampling creates a unique advantage over other self-sampling methods through demedicalising and normalising screening, therefore potentially increasing accessibility and participation among underscreened populations who experience most barriers. How this study might affect research, practice or policy Self-sampling including tampon-based self sampling offers a promising, acceptable approach to achieving cancer elimination goals. Implementation of tampon-based self-sampling for HPV should be clear, comprehensive and accessible, incorporating visual aids and simple language while emphasising the rationale and scientific evidence behind the collection method
- Open Access
- 14 May 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (5) , e0185224
Diagnostic accuracy of the Daye diagnostic tampon compared to clinician-collected and self-collected vaginal swabs for detecting HPV: a comparative study
Cervical cancer screening is vital for achieving global elimination of this preventable disease. Vaginal self-sampling (VSS) for human papillomavirus (HPV) has the potential to increase screening uptake, particularly among individuals who may be underserved by clinician collection. Expanding self-sampling options with accurate, acceptable collection devices is essential. The Daye diagnostic tampon (DDT) offers an innovative approach, utilizing a tampon for HPV-based detection. This study assessed the diagnostic accuracy of DDT in detecting high-risk HPV infections, using vaginal clinician-collected swabs (CCS) as the reference standard. In this UK-based study, 260 participants provided CCS and VSS (with Copan FLOQSwabs) and DDT samples for HPV testing. Samples were analyzed using the Aptima HPV assay, which detects 14 high-risk HPV types. The sensitivity, specificity, positive predictive value, and negative predictive value of the DDT were evaluated against the CCS. Invalidity rates—HPV-negative results with negative internal controls—were compared across sampling methods. The DDT showed a sensitivity of 82.9% [95% confidence interval (CI): 72.4%–89.9%], specificity of 91.6% (CI: 86.4%–94.9%), and overall accuracy of 89.0% (CI: 84.4%–92.4%) relative to CCS. McNemar’s test showed no significant difference between CCS and DDT results ( P = 0.845). Valid result rates were highest for DDT (99.2%), followed by VSS (95.4%) and CCS (90.8%). The DDT demonstrates comparable accuracy to CCS for detecting high-risk HPV. This novel device shows promise as a self-sampling method. Furthermore, complementary research should focus on assessing DDT’s clinical performance in detecting HPV associated with cervical disease endpoints. IMPORTANCE: Cervical cancer remains a leading preventable cause of cancer death globally, with persistent disparities in screening access. Self-sampling for HPV has emerged as a critical tool to improve screening uptake, particularly among underserved populations, yet device acceptability and diagnostic reliability remain barriers to equitable implementation. This study demonstrates that the Daye diagnostic tampon (DDT), a novel, tampon-based self-sampling method, achieves diagnostic accuracy comparable to clinician-collected swabs (sensitivity 82.9% and specificity 91.6%) while yielding fewer invalid results (0.8%) than conventional swabs. By aligning with a familiar menstrual product, the DDT addresses usability concerns that hinder confidence in existing self-sampling devices, as evidenced by 70.5% participant preference in focus groups. These findings advance progress toward World Health Organisation (WHO) cervical cancer elimination targets by validating a culturally resonant, high-performance alternative to clinic-based sampling. The DDT’s potential to expand screening access, especially in low-resource settings or among individuals avoiding pelvic exams, could transform preventive care landscapes, reducing disparities in a disease rooted in healthcare inequity.
- 14 May 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (5) , e0185224
Open AccessDiagnostic accuracy of the Daye diagnostic tampon compared to clinician-collected and self-collected vaginal swabs for detecting HPV: a comparative study
Cervical cancer screening is vital for achieving global elimination of this preventable disease. Vaginal self-sampling (VSS) for human papillomavirus (HPV) has the potential to increase screening uptake, particularly among individuals who may be underserved by clinician collection. Expanding self-sampling options with accurate, acceptable collection devices is essential. The Daye diagnostic tampon (DDT) offers an innovative approach, utilizing a tampon for HPV-based detection. This study assessed the diagnostic accuracy of DDT in detecting high-risk HPV infections, using vaginal clinician-collected swabs (CCS) as the reference standard. In this UK-based study, 260 participants provided CCS and VSS (with Copan FLOQSwabs) and DDT samples for HPV testing. Samples were analyzed using the Aptima HPV assay, which detects 14 high-risk HPV types. The sensitivity, specificity, positive predictive value, and negative predictive value of the DDT were evaluated against the CCS. Invalidity rates—HPV-negative results with negative internal controls—were compared across sampling methods. The DDT showed a sensitivity of 82.9% [95% confidence interval (CI): 72.4%–89.9%], specificity of 91.6% (CI: 86.4%–94.9%), and overall accuracy of 89.0% (CI: 84.4%–92.4%) relative to CCS. McNemar’s test showed no significant difference between CCS and DDT results ( P = 0.845). Valid result rates were highest for DDT (99.2%), followed by VSS (95.4%) and CCS (90.8%). The DDT demonstrates comparable accuracy to CCS for detecting high-risk HPV. This novel device shows promise as a self-sampling method. Furthermore, complementary research should focus on assessing DDT’s clinical performance in detecting HPV associated with cervical disease endpoints. IMPORTANCE: Cervical cancer remains a leading preventable cause of cancer death globally, with persistent disparities in screening access. Self-sampling for HPV has emerged as a critical tool to improve screening uptake, particularly among underserved populations, yet device acceptability and diagnostic reliability remain barriers to equitable implementation. This study demonstrates that the Daye diagnostic tampon (DDT), a novel, tampon-based self-sampling method, achieves diagnostic accuracy comparable to clinician-collected swabs (sensitivity 82.9% and specificity 91.6%) while yielding fewer invalid results (0.8%) than conventional swabs. By aligning with a familiar menstrual product, the DDT addresses usability concerns that hinder confidence in existing self-sampling devices, as evidenced by 70.5% participant preference in focus groups. These findings advance progress toward World Health Organisation (WHO) cervical cancer elimination targets by validating a culturally resonant, high-performance alternative to clinic-based sampling. The DDT’s potential to expand screening access, especially in low-resource settings or among individuals avoiding pelvic exams, could transform preventive care landscapes, reducing disparities in a disease rooted in healthcare inequity.
- 19 February 2025
- Published by Elsevier in Journal of Adolescent Health
- Vol. 77 (2) , 229-236
Assessing the Impact of a Routine Requirement for In-Person Abortion Care for Adolescents in England and Wales: A Prepost Evaluation
- 19 February 2025
- Published by Elsevier in Journal of Adolescent Health
- Vol. 77 (2) , 229-236
Assessing the Impact of a Routine Requirement for In-Person Abortion Care for Adolescents in England and Wales: A Prepost Evaluation
- Top Cited PapersOpen Access
- 13 January 2025
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 51 (3) , 186-190
Self-reported contraceptive method use at conception among patients presenting for abortion in England: a cross-sectional analysis comparing 2018 and 2023
Background: Recent media attention has been given to an apparent shift away from hormonal methods of contraception. While an increase in fertility awareness-based or ‘natural’ family planning methods is reported in the grey literature, there are no robust data to determine any such trend in the UK. Methods: We compared self-reported contraceptive use at conception among patients presenting for abortion at British Pregnancy Advisory Service from January to June 2018 (N=33 495) and January to June 2023 (N=55 055) using chi-square (χ2) tests of association. Results: Reported use of fertility awareness-based methods of contraception around the time of conception increased from 0.4% in 2018 to 2.5% in 2023 (p<0.001). In contrast, use of hormonal methods of contraception decreased from 18.8% in 2018 to 11.3% in 2023 (p<0.001) and use of long-acting reversible contraception fell from 3% to 0.6% (p<0.001). Those reporting using no contraception at the time of conception significantly increased by 14% (p<0.001) when comparing data from 2018 (55.8%) with data from 2023 (69.6%). Conclusions: Significantly fewer abortion patients report using effective methods of contraception around conception while also reporting an increased use of fertility awareness-based methods. Further research is needed to understand the reasons for this change.
- 13 January 2025
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 51 (3) , 186-190
Top Cited PapersOpen AccessSelf-reported contraceptive method use at conception among patients presenting for abortion in England: a cross-sectional analysis comparing 2018 and 2023
Background: Recent media attention has been given to an apparent shift away from hormonal methods of contraception. While an increase in fertility awareness-based or ‘natural’ family planning methods is reported in the grey literature, there are no robust data to determine any such trend in the UK. Methods: We compared self-reported contraceptive use at conception among patients presenting for abortion at British Pregnancy Advisory Service from January to June 2018 (N=33 495) and January to June 2023 (N=55 055) using chi-square (χ2) tests of association. Results: Reported use of fertility awareness-based methods of contraception around the time of conception increased from 0.4% in 2018 to 2.5% in 2023 (p<0.001). In contrast, use of hormonal methods of contraception decreased from 18.8% in 2018 to 11.3% in 2023 (p<0.001) and use of long-acting reversible contraception fell from 3% to 0.6% (p<0.001). Those reporting using no contraception at the time of conception significantly increased by 14% (p<0.001) when comparing data from 2018 (55.8%) with data from 2023 (69.6%). Conclusions: Significantly fewer abortion patients report using effective methods of contraception around conception while also reporting an increased use of fertility awareness-based methods. Further research is needed to understand the reasons for this change.
- Open Access
- 18 December 2024
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 51 (2) , 137-143
Expectations and experiences of pain during medical abortion at home: a secondary, mixed-methods analysis of a patient survey in England and Wales
Objective To explore experiences of pain during medical abortion and provide patient-centred recommendations for improving abortion experience and pain counselling. Methods We invited patients of British Pregnancy Advisory Service who underwent medical abortion up to 10 weeks’ gestation to participate in an online, English language questionnaire from November 2021 to March 2022. Participants answered questions about pain, method preference, abortion experience, advice, and how they would describe pain experienced to a friend. In this secondary analysis, we analysed free-text responses using reflexive thematic analysis techniques. We used descriptive statistics and parametric tests to analyse quantitative responses. Results Of 11 906 patients invited to participate, 1596 (13.4%) completed the questionnaire, including at least one free-text comment. Participants used a range of descriptors for medical abortion pain across three broad themes: pain severity, pain quality and comparisons to other reproductive pain. Some found the commonly used analogy to period pain misleading. Many felt unprepared for the level of pain they experienced, which they attributed to provider comparisons to period pain, as well as a lack of detailed, realistic anticipatory pain counselling. Qualitative and quantitative results suggest pain experiences impact method preference. Participants recommended better counselling for pain and abortion preparation, including first-hand accounts of medical abortion at home and a wide and accessible range of descriptions of pain. Conclusions Abortion providers should use patient-centred recommendations to better prepare patients for pain during medical abortion. Setting realistic expectations can improve abortion experience and support informed method choice. Further research is needed to develop and test patient-centred counselling materials.
- 18 December 2024
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 51 (2) , 137-143
Open AccessExpectations and experiences of pain during medical abortion at home: a secondary, mixed-methods analysis of a patient survey in England and Wales
Objective To explore experiences of pain during medical abortion and provide patient-centred recommendations for improving abortion experience and pain counselling. Methods We invited patients of British Pregnancy Advisory Service who underwent medical abortion up to 10 weeks’ gestation to participate in an online, English language questionnaire from November 2021 to March 2022. Participants answered questions about pain, method preference, abortion experience, advice, and how they would describe pain experienced to a friend. In this secondary analysis, we analysed free-text responses using reflexive thematic analysis techniques. We used descriptive statistics and parametric tests to analyse quantitative responses. Results Of 11 906 patients invited to participate, 1596 (13.4%) completed the questionnaire, including at least one free-text comment. Participants used a range of descriptors for medical abortion pain across three broad themes: pain severity, pain quality and comparisons to other reproductive pain. Some found the commonly used analogy to period pain misleading. Many felt unprepared for the level of pain they experienced, which they attributed to provider comparisons to period pain, as well as a lack of detailed, realistic anticipatory pain counselling. Qualitative and quantitative results suggest pain experiences impact method preference. Participants recommended better counselling for pain and abortion preparation, including first-hand accounts of medical abortion at home and a wide and accessible range of descriptions of pain. Conclusions Abortion providers should use patient-centred recommendations to better prepare patients for pain during medical abortion. Setting realistic expectations can improve abortion experience and support informed method choice. Further research is needed to develop and test patient-centred counselling materials.
- Open Access
Diagnostic Accuracy of the Daye Diagnostic Tampon Compared to Clinician-Collected and Self-Collected Vaginal Swabs for Detecting HPV: A Comparative Study
Introduction Cervical cancer screening is vital for achieving global elimination of this preventable disease. Vaginal self-sampling (VSS) for human papillomavirus (HPV) has the potential to increase screening uptake, particularly among individuals who may be underserved by clinician collection. Expanding self-sampling options with accurate, acceptable collection devices is essential. The Daye Diagnostic Tampon (DDT) offers an innovative approach, utilising a menstrual tampon to collect vaginal and cervical fluid for HPV screening. This study assessed the diagnostic accuracy of the DDT in detecting high-risk HPV infections, using clinician-collected swabs (CCS) as the reference standard. Methods In this UK-based study, 260 participants provided CCS, VSS, and DDT samples for HPV testing. Samples were analysed using a clinically validated assay for 14 high-risk HPV types. Sensitivity, specificity, positive predictive value, and negative predictive value of the DDT were evaluated against CCS. Invalidity rates—HPV-negative results with negative internal controls—were compared across sampling methods. Results The DDT showed a sensitivity of 82.9% (95% CI:72.4–89.9%), specificity of 91.6% (CI:86.4–94.9%), and overall accuracy of 89.0% (CI:84.4–92.4%) relative to CCS. McNemar’s test showed no significant difference between CCS and DDT results (p = 0.845). Valid result rates were highest for DDT (99.2%), followed by VSS (95.4%) and CCS (90.8%). Conclusion The DDT demonstrates comparable accuracy to CCS for detecting high-risk HPV. This novel device shows promise as a self-sampling method. Further, complementary research should focus on assessing DDT’s clinical performance in detecting HPV associated with cervical disease endpoints.
Open AccessDiagnostic Accuracy of the Daye Diagnostic Tampon Compared to Clinician-Collected and Self-Collected Vaginal Swabs for Detecting HPV: A Comparative Study
Introduction Cervical cancer screening is vital for achieving global elimination of this preventable disease. Vaginal self-sampling (VSS) for human papillomavirus (HPV) has the potential to increase screening uptake, particularly among individuals who may be underserved by clinician collection. Expanding self-sampling options with accurate, acceptable collection devices is essential. The Daye Diagnostic Tampon (DDT) offers an innovative approach, utilising a menstrual tampon to collect vaginal and cervical fluid for HPV screening. This study assessed the diagnostic accuracy of the DDT in detecting high-risk HPV infections, using clinician-collected swabs (CCS) as the reference standard. Methods In this UK-based study, 260 participants provided CCS, VSS, and DDT samples for HPV testing. Samples were analysed using a clinically validated assay for 14 high-risk HPV types. Sensitivity, specificity, positive predictive value, and negative predictive value of the DDT were evaluated against CCS. Invalidity rates—HPV-negative results with negative internal controls—were compared across sampling methods. Results The DDT showed a sensitivity of 82.9% (95% CI:72.4–89.9%), specificity of 91.6% (CI:86.4–94.9%), and overall accuracy of 89.0% (CI:84.4–92.4%) relative to CCS. McNemar’s test showed no significant difference between CCS and DDT results (p = 0.845). Valid result rates were highest for DDT (99.2%), followed by VSS (95.4%) and CCS (90.8%). Conclusion The DDT demonstrates comparable accuracy to CCS for detecting high-risk HPV. This novel device shows promise as a self-sampling method. Further, complementary research should focus on assessing DDT’s clinical performance in detecting HPV associated with cervical disease endpoints.
- 30 January 2024
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 50 (2) , 114-121
Opt-in versus universal codeine provision for medical abortion up to 10 weeks of gestation at British Pregnancy Advisory Service: a cross-sectional evaluation
Objective To assess patient experiences of pain management during medical abortion up to 10 weeks’ gestation with opt-in versus universal codeine provision. Methods We invited patients who underwent medical abortion up to 10 weeks of gestation to participate in an online, anonymous, English-language survey from November 2021 to March 2022. We performed ordinal regression analyses to compare satisfaction with pain management (5-point Likert scale) and maximum abortion pain score (11-point numerical rating scale) in the opt-in versus universal codeine provision groups. Results Of 11 906 patients invited to participate, 1625 (13.6%) completed the survey. Participants reported a mean maximum pain score of 6.8±2.2. A total of 1149 participants (70.7%) reported using codeine for pain management during their abortion. Participants in the opt-in codeine provision group were significantly more likely to be satisfied with their pain management than those in the universal group (aOR 1.48, 95% CI 1.12 to 1.96, pConclusion Our findings suggest that patients have a better experience with pain management during medical abortion when able to opt-in to codeine provision following counselling versus receiving this medication routinely.
- 30 January 2024
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 50 (2) , 114-121
Opt-in versus universal codeine provision for medical abortion up to 10 weeks of gestation at British Pregnancy Advisory Service: a cross-sectional evaluation
Objective To assess patient experiences of pain management during medical abortion up to 10 weeks’ gestation with opt-in versus universal codeine provision. Methods We invited patients who underwent medical abortion up to 10 weeks of gestation to participate in an online, anonymous, English-language survey from November 2021 to March 2022. We performed ordinal regression analyses to compare satisfaction with pain management (5-point Likert scale) and maximum abortion pain score (11-point numerical rating scale) in the opt-in versus universal codeine provision groups. Results Of 11 906 patients invited to participate, 1625 (13.6%) completed the survey. Participants reported a mean maximum pain score of 6.8±2.2. A total of 1149 participants (70.7%) reported using codeine for pain management during their abortion. Participants in the opt-in codeine provision group were significantly more likely to be satisfied with their pain management than those in the universal group (aOR 1.48, 95% CI 1.12 to 1.96, pConclusion Our findings suggest that patients have a better experience with pain management during medical abortion when able to opt-in to codeine provision following counselling versus receiving this medication routinely.
- Open Access
Agreement between self-reported and researcher-measured height, weight and blood pressure measurements for online prescription of the combined oral contraceptive pill: an observational study
Objective(s): To compare agreement between self-reported height, weight and blood pressure measurements submitted to an online contraceptive service with researcher-measured values and document strategies used for self-reporting.Design: An observational study.Setting: An online sexual health service which provided the combined oral contraceptive pill, free of charge, to users in Southeast London, England.Participants: Between August 2017 and August 2019, 365 participants were recruited.Primary and secondary outcome measures: The primary outcome, for which the study was powered, was the agreement between self-reported and researcher-measured body mass index (BMI) and blood pressure measurements, compared using kappa coefficients. Secondary measures of agreement included sensitivity, specificity and Bland Altman plots. The study also describes strategies used for self-reporting and classifies their clinical appropriateness.Results: 327 participants fully described their process of blood pressure measurement with 296 (90.5%) classified as clinically appropriate. Agreement between self-reported and researcher-measured BMI was substantial (0.72 (95% CI 0.42 to 1.0)), but poor for blood pressure (0.06 (95% CI −0.11 to 0.23)). Self-reported height and weight readings identified 80.0% (95% CI 28.4 to 99.5) of individuals with a researcher-measured high BMI (≥than 35 kg/m2) and 9.1% (95% CI 0.23 to 41.3) of participants with a researcher-measured high blood pressure (≥140/90 mm Hg).Conclusion: In this study, while self-reported BMI was found to have substantial agreement with researcher-measured BMI, self-reported blood pressure was shown to have poor agreement with researcher-measured blood pressure. This may be due to the inherent variability of blood pressure, overdiagnosis of hypertension by researchers due to ‘white coat syndrome’ or inaccurate self-reporting. Strategies to improve self-reporting of blood pressure for remote prescription of the combined pill are needed.
Open AccessAgreement between self-reported and researcher-measured height, weight and blood pressure measurements for online prescription of the combined oral contraceptive pill: an observational study
Objective(s): To compare agreement between self-reported height, weight and blood pressure measurements submitted to an online contraceptive service with researcher-measured values and document strategies used for self-reporting.Design: An observational study.Setting: An online sexual health service which provided the combined oral contraceptive pill, free of charge, to users in Southeast London, England.Participants: Between August 2017 and August 2019, 365 participants were recruited.Primary and secondary outcome measures: The primary outcome, for which the study was powered, was the agreement between self-reported and researcher-measured body mass index (BMI) and blood pressure measurements, compared using kappa coefficients. Secondary measures of agreement included sensitivity, specificity and Bland Altman plots. The study also describes strategies used for self-reporting and classifies their clinical appropriateness.Results: 327 participants fully described their process of blood pressure measurement with 296 (90.5%) classified as clinically appropriate. Agreement between self-reported and researcher-measured BMI was substantial (0.72 (95% CI 0.42 to 1.0)), but poor for blood pressure (0.06 (95% CI −0.11 to 0.23)). Self-reported height and weight readings identified 80.0% (95% CI 28.4 to 99.5) of individuals with a researcher-measured high BMI (≥than 35 kg/m2) and 9.1% (95% CI 0.23 to 41.3) of participants with a researcher-measured high blood pressure (≥140/90 mm Hg).Conclusion: In this study, while self-reported BMI was found to have substantial agreement with researcher-measured BMI, self-reported blood pressure was shown to have poor agreement with researcher-measured blood pressure. This may be due to the inherent variability of blood pressure, overdiagnosis of hypertension by researchers due to ‘white coat syndrome’ or inaccurate self-reporting. Strategies to improve self-reporting of blood pressure for remote prescription of the combined pill are needed.
- Open Access
- 9 February 2021
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 47 (3) , 157-158
Supporting blood pressure measurement prior to online prescription of the combined oral contraceptive
- 9 February 2021
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 47 (3) , 157-158
Open AccessSupporting blood pressure measurement prior to online prescription of the combined oral contraceptive